Compare AU
Compare DRUG vs. MVE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the S&P Aussie 50 Mid-Caps (MVE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | MVE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 36 |
Median incremental investment | $920.50 | $669.89 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,870.68 | $2,940.44 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | MVE | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | MVE.AX was created on 2013-10-14 by VanEck. The fund's investment portfolio concentrates primarily on mid cap equity. The Fund is designed to capture the performance of the 50 midcap companies listed on ASX having Market Capitalisation ranking from 51 to 100. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Pro Medicus Ltd (4.65 %) REA Group Ltd (4.06 %) JB Hi Fi Ltd (3.51 %) |
Top 3 industries | Other (76.23 %) Communication Services (33.53 %) Health Care (23.66 %) | Information Technology (19.22 %) Materials (17.94 %) Health Care (13.71 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (94.11 %) New Zealand (3.28 %) United States (2.61 %) |
Management fee | 0.57 % | 0.45 % |
Key Summary
DRUG | MVE | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX Midcap 50 Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.45 % |
Price | $7.89 | $39.82 |
Size | $183.079 million | $315.482 million |
10Y return | N/A | 97.81 % |
Annual distribution yield (5Y) | 1.90 % | 3.49 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 16/10/2013 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | MVE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 36 |
Median incremental investment | $920.50 | $669.89 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,870.68 | $2,940.44 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | MVE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | MVE |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |